New drug shows promise against rare liver infection

NCT ID NCT06505928

Ongoing Disease control Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a new drug called hepalatide (L47) in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of hepalatide daily for 48 weeks, or delayed treatment. The main goal is to see if the drug can lower the virus level and improve liver health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hepalatide (L47), a drug given as a daily injection
What this could lead to: If it works, this could point toward a new treatment option for chronic hepatitis D, a serious liver disease with few approved therapies.
What could go wrong: This is an early Phase 2 trial with only 90 participants, so results may not apply to everyone. The drug may not show enough benefit or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS D are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS D

Contacts and locations

Locations

National Center for Communicable Diseases

Ulaanbaatar, Mongolia
National cancer canter of Monglia

Ulaanbaatar, 13370, Mongolia

More trials for these conditions

Other studies related to the condition(s) this trial covers.